Drug Profile
Research programme: CNS/pain antibody therapeutics - Adimab/Pfizer
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Adimab; Pfizer
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Neurological-disorders in USA
- 30 Aug 2011 Early research is ongoing in USA
- 18 Dec 2009 Early research in Neurological disorders in USA (unspecified route)